Business Context and Reporting Period
Company: BioLife Solutions, Inc. (BLFS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended September 30, 2025
Business Overview: BioLife develops and markets bioproduction products and services for the cell and gene therapy (CGT) industry, including biopreservation media, automated thawing devices, and cloud-connected shipping containers. The company operates as a single reportable segment.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Total Revenue | $28.1 million | $21.4 million | $77.4 million | $59.5 million |
| Net Income (Loss) | $0.6 million | $(1.7) million | $(15.7) million | $(32.6) million |
| Operating Loss | $(0.1) million | $(0.4) million | $(17.9) million | $(5.0) million |
| Cash & Equivalents | $29.5 million | $35.4 million (Sep 2024) | $29.5 million (Sep 2025) | $35.4 million (Sep 2024) |
| Total Liquid Assets (Cash + AFS Securities) |
$98.4 million | $44.6 million (Sep 2024) | $98.4 million | $44.6 million |
| Debt (Current + Long-Term) | $7.5 million | $15.9 million | $7.5 million | $15.9 million |
| Operating Cash Flow | N/A | N/A | $15.2 million | $6.8 million |
Note: Net Income for Q3 2025 includes a $0.6 million gain from continuing operations. YTD 2025 Net Loss includes a $15.5 million non-cash In-Process Research and Development (IPR&D) expense related to the PanTHERA acquisition.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 31% in Q3 2025 and 30% YTD 2025 compared to the prior year. This was driven primarily by a 33% increase in cell processing product revenue due to higher demand from customers with commercially approved therapies.
- Profitability: The company returned to profitability in Q3 2025 with $0.6 million net income, compared to a $1.7 million loss in Q3 2024. However, YTD 2025 remains loss-making at $(15.7) million, heavily impacted by the $15.5 million IPR&D expense from the PanTHERA acquisition.
- Expense Increases: General and Administrative (G&A) expenses rose 29% in Q3 and 20% YTD, driven by higher personnel costs, stock-based compensation, and professional fees. R&D expenses increased 43% in Q3 and 27% YTD.
- Liquidity Position: Cash and cash equivalents decreased from $95.4 million at year-end 2024 to $29.5 million at September 30, 2025. However, total liquid assets (including available-for-sale securities) increased to $98.4 million due to significant investment purchases ($77.4 million in AFS securities).
- Debt Reduction: Total debt decreased from $15.9 million to $7.5 million as the company made $7.5 million in term loan payments during the nine months ended September 30, 2025.
Guidance, Outlook, and Risks
- Acquisitions & Divestitures:
- PanTHERA: Acquired remaining 90% stake in April 2025 for $16.8 million (cash and stock). The $15.5 million IPR&D asset was immediately expensed. An earn-out of up to $7.2 million is possible based on future revenue targets.
- SAVSU Divestiture (Subsequent Event): On October 6, 2025, the company agreed to sell its SAVSU business (evo shipping containers) for $25.5 million. This is expected to be classified as a discontinued operation in the 2025 10-K.
- Discontinued Operations: Global Cooling, SciSafe, and CBS businesses were divested in 2024 and are reported as discontinued operations.
- Liquidity Outlook: Management believes current cash and liquid assets are sufficient to meet needs for at least the next 12 months.
- Risks & Contingencies:
- Legal: The company faces indemnification obligations for two lawsuits related to Global Cooling's pre-divestiture products (claims totaling up to $5.4 million), though management expects insurance to cover these losses.
- Tax: A full valuation allowance of $56.8 million is maintained against deferred tax assets due to uncertainty regarding future realizability.
- Market: Risks include global trade policy volatility, tariffs, and high interest rates.
Investor Verification Checklist
- SAVSU Transaction Accounting: Verify the final accounting treatment and timing of the $25.5 million SAVSU divestiture proceeds, as it was a subsequent event to the reporting period.
- PanTHERA Earn-Out Probability: Assess the likelihood of achieving the revenue targets required to trigger the $7.2 million earn-out payment.
- IPR&D Expense Impact: Confirm that the $15.5 million expense is a one-time non-cash item and review the commercial viability timeline for the acquired IRI GEN 2 technology.
- Legal Indemnification: Monitor the status of the Global Cooling product liability lawsuits and the enforceability of the insurance coverage.
- Customer Concentration: Review the dependency on top customers (Customer A, B, C, D) which collectively represent significant portions of revenue and accounts receivable.